Atopic dermatitis: Review of immunopathogenesis and advances in immunosuppressive therapy

Australasian Journal of Dermatology

Volumn 43, Issue 4, 2002, Pages 247-254

  Meagher, Linton J ^a   Wines, Nina Y ^a   Cooper, Alan J ^a  

^a NONE   (Australia)

Author keywords

Azathioprine; Corticosteroids; Cyclosporin; Eczema; Immunosuppression; Pimecrolimus; Tacrolimus

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CONTACT ALLERGEN; CYCLIC AMP; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; IMMUNOSUPPRESSIVE AGENT; IRRITANT AGENT; METHOTREXATE; PHOSPHODIESTERASE INHIBITOR; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; CELLULAR IMMUNITY; CLIMATE; CLINICAL TRIAL; DISEASE PREDISPOSITION; EGG; EOSINOPHIL; FOOD; GENETICS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INHALATION; LEUKOCYTE; MICROORGANISM; MILK; MONOCYTE; PEANUT; PITYROSPORUM OVALE; PROTEIN EXPRESSION; PRURITUS; PSYCHOSOMATIC DISORDER; REVIEW; SKIN FUNCTION; SOYBEAN; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; WHEAT;

DERMATITIS, ATOPIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0036436842     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.2002.00610.x     Document Type: Review

References (80)

1. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet 1998; 351: 1715-21.
2. Leung YM. Pathogenesis of atopic dermatitis. J. Allergy Clin. Immunol. 1999; 104 (Suppl. 3): S99-106.
3. Bos JD, Hagenara C, Das PK, Kreig SR, Voorn WJ, Kapsenberg ML. Predominance of 'memory' T cells (CD4+, CDw29+) over 'naïve' T cells in both normal and diseased human skin. Arch. Dermatol. Res. 1989; 81: 24-30.
4. Uehara M, Kimura C. Descendent family history of atopic dermatitis. Acta Derm. Venereol. 1993; 73: 62-3.
5. Barnes KC. Evidence for common genetic elements in allergic disease. J. Allergy Clin. Immunol. 2000; 106: 192-200.
6. Thestrup-Pedersen K, Ellingsen AR, Olesen AB, Lund M, Kaltoft K. Atopic dermatitis may be genetically determined dysmaturation of ectodermal tissue, resulting in disturbed T-lymphocyte maturation: A hypothesis. Acta Derm. Venereol. 1997; 77: 20-1.
7. Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: New targets for emerging therapies. J. Am. Acad. Dermatol. 1999; 41: 72-7.
8. Cookson WO, Ubhi B, Lawrence R, Abecasis GR, Walley AJ, Cox HE et al. A major susceptibility locus for atopic dermatitis and psoriasis susceptibility loci. Nat. Genet. 2001; 26: 470-3.
9. Rajka G. Itch duration of the uninvolved skin of atopic dermatitis (prurigo Besnier). Acta Derm. Venereol. 1968; 48: 320-1.
10. Nickoloff BJ, Naidu Y. Pertubation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad. Dermatol. 1994; 30: 535-46.
11. Wahlgren CF, Hagermark O, Bergstrom R. Patients perception of itch induced by histamine, 44/80, and wool fibres in atopic dermatitis. Acta Derm. Venereol. 1991; 71: 488-94.
12. Ruzicka T. Atopic eczema: Between rationality and irrationality. Arch. Dermatol. 1998; 134: 1462-9.
13. Parish WE. Inflammation. In: Champion RH, Burton JL, Burns DA, Breathnach SM (eds). Textbook of Dermatology, Vol. 1, 6th Edn. Oxford: Blackwell Science, 1998; 229-76 (265).
14. Lydyard P, Grossi C. Cells involved in the immune response. In: Roitt I, Brostoff J, Male D (eds). Immunology, 5th Edn. London: Mosby International Publishing, 1998; 14-26.
15. Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine gene expression in acute vs. chronic atopic dermatitis. J. Clin. Invest. 1994; 94: 870-6.
16. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DYM. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J. Allergy Clin. Immunol. 1996; 98: 225-31.
17. Uno H, Hanifin JM. Langerhans cells in acute and chronic epidermal lesions of atopic dermatitis, observed by L-dopa histofluorescence, glycol methacrylate thin section, and electron microscopy. J. Invest. Dermatol. 1980; 75: 52-60.
18. Ohki O, Yokozeki H, Katayama I. Functional CD86 (B7-2/B70) is predominantly expressed on Langerhan cells in atopic dermatitis. Br. J. Dermatol. 1997; 136: 838-45.
19. Beltrani V. The clinical spectrum of atopic dermatitis. J. Allergy Clin. Immunol. 1999; 104 (Suppl. 3): S87-96.
20. Santamaria-Babi LF. Skin-homing T cells in human cutaneous allergic inflammation. Immunol. Res. 1995; 14: 317-24.
21. Koide M, Furukawa F, Tokura Y, Shirahama S, Takigawa M. Evaluation of soluble cell adhesion molecules in atopic dermatitis. J. Dermatol. 1997; 24: 88-93.
22. Elliot ST, Hanifin JM. Delayed cutaneous hypersensitivity and lymphocyte transformation: Dissociation in atopic dermatitis. Arch. Dermatol. 1979; 115: 36-9.
23. Zachary CB, Allen MH, MacDonald DM. In situ quantification of T-lymphocyte subsets and Langerhans cells in the inflam-matory infiltrate of atopic eczema. Br. J. Dermatol. 1985; 112: 149-56.
24. Ohmen JD, Hannifin JM, Nickoloff BJ, Rea TH, Wyzykowski R, Kim J et al. Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J. Immunol. 1995; 154: 1956-63.
25. Arkwright PD, Chase JM, Babbage S, Pravica V, David TJ, Hutchinson IV. Atopic dermatitis is associated with a low-producer transforming growth factor beta1 cytokine genotype. J. Allergy Clin. Immunol. 2001; 108: 281-4.
26. Jones HE, Inouye JC, McGerity JL, Lewis CW. Atopic disease and serum immunoglobulin-E. Br. J. Dermatol. 1975; 92: 17-25.
27. Peterson RD, Page AR, Good RA. Wheal and erythema allergy in patients with agammaglobulinaemia. J. Allergy 1966; 33: 406-11.
28. Bieber T, de la Salle C, Wollenberg A, Chizzonite R, Hakimi J. Human Langerhans cells express high affinity receptor for immunoglobulin E. J. Exp. Med. 1992; 175: 1285-90.
29. Bruynzeel-Komen CA, van Wichen DF, Toonstra J, Berrens L, Bruynzeel PL. The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch. Dermatol. Res. 1986; 278: 199-205.
30. Taylor RS, Baadsgaard O, Hammerberg C, Cooper KD. Hyper-stimulatory CD1a+CD1b+CD36+ Langerhans cells are responsible for increased autologous T lymphocyte reactivity to lesional epidermal cells of patients with atopic dermatitis. J. Immunol. 1991; 147: 3794-802.
31. Mudde GC, Van Reijsen FC, Boland GJ, De Gast GC, Bruijnkeel PL, Bruijnkeel-Koomen CA. Allergen presentation by epidermal cells from patients with atopic dermatitis is mediated by IgE. Immunology 1990; 69: 335-41.
32. Valenta R, Maurer D, Steiner R, Seiberler S, Sperr WR, Valent P et al. Immunoglobulin E response to human proteins in atopic patients. J. Invest. Dermatol. 1996; 107: 203-8.
33. Quinti I, Brozek C, Geha RS, Leung DYM. Circulating IgG antibodies to IgE in atopic syndromes. J. Allergy Clin. Immunol. 1986; 77: 586-94.
34. Valenta R, Natter S, Seiberler S. Molecular characterisation of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. J. Invest. Dermatol. 1998; 111: 1178-83.
35. Leiferman KM, Ackerman SJ, Sampson HA, Haugen HS, Venencie PY, Gleich GJ. Dermal deposition of eosinophilgranule major basic protein in atopic dermatitis. N. Engl. J. Med. 1985; 313: 282-5.
36. Ott NL, Gleich GJ, Peterson EA, Fujisawa T, Sur S, Leiferman KM. Assessment of eosinophil and neutrophil participation in atopic dermatitis: Comparison with the IgE- mediated late phase reaction. J. Allergy Clin. Immunol. 1994; 94: 120-8.
37. Hanifin JM, Lobitz WC. Newer concepts of atopic dermatitis. Arch. Dermatol. 1977; 113: 663-70.
38. Taha RA, Minshall EM, Leung DY, Boguniewicz M, Luster A, Muro S et al. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J. Allergy Clin. Immunol. 2000; 105: 1002-7.
39. Taha RA, Minshall EM, Miotto D, Shimbara A, Luster A, Hogg JC et al. Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and nonasthmatic individuals. J. Allergy Clin. Immunol. 1999; 103: 476-83.
40. Grewe SR, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: A possible mechanism for cyclic AMP-agonist hyperresponsiveness. J. Allergy Clin. Immunol. 1982; 70: 452-7.
41. Hanifin JM, Chan SC, Cheng JB, Toffe SJ, Henderson WR Jr, Kirby DS. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol. 1996; 107: 51-6.
42. Ho S, Clipstone N, Timmerman L, Northrop J, Graef I, Florentino D. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 1996; 80 (Suppl. 3): S40-5.
43. Leyden JE, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br. J. Dermatol. 1974; 90: 25-30.
44. Leung DY, Harbeck R, Bina P, Reiser RF, Yang E, Norris DA et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J. Clin. Invest. 1993; 92: 1374-80.
45. Neuber K, Koenig W, Ring J.Staphylococcus aureus and atopic dermatitis. Hautarzt 1993; 44: 135-42 (In German with English abstract).
46. Eedy DJ. What's new in atopic dermatitis? Br. J. Dermatol. 2001; 145: 380-4.
47. Kieffer M, Bergbrant IM, Faergemann J, Jemec GB, Ottevanger V, Stahl Skov P et al. Immune reactions to Pityrosporum ovale in adult patients with atopic and seborrheic dermatitis. J. Am. Acad. Dermatol. 1990; 22: 739-42.
48. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of house dust-mite allergen avoidance on atopic dermatitis. Lancet 1996; 347: 8-15.
49. Eigenmann PA, Sicherer SH, Borkowski T, Cohen BA, Sampson HA. Prevalence of IgE mediated food allergy among children with atopic dermatitis. Pediatrics 1998; 101: 463-4.
50. Van Reijsen FC, Felius A, Wauters AK, Bruijnzeel-Koomen C, Koppelman SJ. T-cell reactivity for a peanut-derived epitope in the skin of a young infant with atopic dermatitis. J. Allergy Clin. Immunol. 1998; 101: 207-9.
51. Sampson HA. Food sensitivity and the pathogenesis of atopic dermatitis. J. R. Soc. Med. 1997; 90: 2-8.
52. Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J. Allergy Clin. Immunol. 2001; 107: 891-6.
53. Roehr CC, Riebel S, Ziegert M, Sommerfield C, Wahn U, Niggermann B. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis. J. Allergy Clin. Immunol. 2001; 107: 548-53.
54. Sampson HA, Scanlon SM. Natural history of food hypersensitivity in children with atopic dermatitis. J. Pediatrics 1989; 115: 23-7.
55. Kusunoki T, Hosoi S, Korematsu S, Asai K, Harazaki M, Furusho K. Re-evaluation of multi-allergen skin prick test for infants with atopic dermatitis-clinical relevance and evaluation by mothers. Arerugi 1998; 47: 726-33 (In Japanese with English abstract).
56. Ansel JC, Kaynard AH, Armstrong CA, Olerud J, Bunnett N, Payan D. Skin: Nervous system interactions. J. Invest. Dermatol. 1996; 106: 198-204.
57. Eberlein-Konig B, Spiegl A, Przybilla B. Change of skin roughness due to lowering of air humidity in climate chamber. Acta Derm. Venereol. 1996; 76: 447-9.
58. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 1992; 357: 695-7.
59. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol. Today 1992; 13: 136-42.
60. Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, English JS, Freeman K et al. Long term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br. J. Dermatol. 1997; 136: 76-81.
61. Granlund H, Erkko P, Remitz A, Langeland T, Helsing P, Nuutinen M et al. Comparison of cyclosporin and UVAB photo-therapy for intermittent one-year treatment of atopic dermatitis. Acta Derm. Venereol. 2001; 81: 22-7.
62. Buckley DA, Baldwin P, Rogers S. The use of azathioprine in the treatment of severe adult atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 1998; 11: 137-40.
63. Younger IR, Harris DWS, Colver GB. Azathioprine in dermatology. J. Am. Acad. Dermatol. 1991; 25: 281-6.
64. Kuanprasert N, Herbert O, Barnetson RStC. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis with oral azathioprine. Australas. J. Derm. 2002; 43: 125-7.
65. Yatscoff RW, Aspeslet LJ. The monitoring of immunosuppressive drugs: A pharmacodynamic approach. Ther. Drug Monit. 1998; 20: 459-63.
66. Seitz M. Molecular and cellular effects of methotrexate. Curr. Opin. Rheumatol. 1999; 11: 226-31.
67. Cronstein BN. The mechanism of action of methotrexate. Rheum. Dis. Clin. North Am. 1997; 23: 739-55.
68. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1586-93.
69. Bagott JE, Vaughan WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem. J. 1986; 236: 193-200.
70. Gruber HE, Hoffer ME, McAllister DR, Laikind PK, Lane TA, Schmid-Schoenbein GW et al. Increased adenosine concentration in blood from ischemic myocardium by AICA-riboside: Effects on flow, granulocytes and injury. Circulation 1989; 80: 1400-11.
71. Fleisher AB Jr. Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical noncorticosteroidal therapy. J. Allergy Clin. Immunol. 1999; 104 (Suppl. 3): S126-30.
72. Hanifin JM, Tofte SJ. Update on therapy of atopic dermatitis. J. Allergy Clin. Immunol. 1999; 104 (Suppl. 3): S123-5.
73. Lawrence ID. Tacrolimus (FK506): Experience in dermatology. Dermatol. Ther. 1998; 5: 74-84.
74. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD et al. A short term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N. Engl. J. Med. 1997; 337: 816-21.
75. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DYM, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children: Pediatric Tacrolimus Study Group. J. Clin. Immunol. 1998; 102: 6387-44.
76. Jujo K, Renz H, Abe J, Gelfland EW, Leung DYM. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. J. Allergy Clin. Immunol. 1992; 90: 323-31.
77. Jang IG, Yang JK, Lee HJ, Yi JY, Kim HO, Kim CW, Kim TY. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J. Am. Acad. Dermatol. 2000; 42: 1033-40.
78. Barnes PJ. New directions in allergic diseases: Mechanism-based anti-inflammatory therapies. J. Allergy Clin. Immunol. 2000; 106: 5-16.
79. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br. J. Dermatol. 1999; 141: 264-73.
80. Van Leent EJM, Graber MD, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch. Dermatol. 1998; 134: 805-9.